Kevin regularly advises clients on organization, strategy and transformation, as well as both commercial and launch excellence. His recent client engagements have involved due diligence and sector screening and review efforts for private equity clients, as well as adjacency and business unit strategy across pharmaceuticals and biotechnology.
While with the firm, Kevin has led a commercial excellence exercise for one of the world's leading IVD manufacturers, which doubled the company’s business in China in 5 years.
He is also deeply involved with our local pro bono efforts.
Kevin holds a B.A. in Economics from Cornell University.
- “The New Board Agenda,” Brief, 19. Oktober 2021
- “China, Deglobalization, and the Multinational,” Artikel, 21. Juli 2021
- “Local Innovation Is Fueling Asia-Pacific’s Healthcare Private Equity Boom,” Video, 28. April 2021
- “Healthcare Private Equity in Asia-Pacific Rides a Wave of Domestic Innovation ,” Snap Chart, 23. März 2021
- “Healthcare Private Equity in Asia-Pacific: Riding a Wave of Domestic Innovation,” Report, 16. März 2021